Truist initiated coverage of NewAmsterdam Pharma with a Buy rating and $57 price target. The stock significantly outperformed in 2024 and 2025 as the company successfully de-risked its lead asset, obicetrapib, with positive Phase 3 data, notes the analyst, who believes the upcoming mid-year PREVAIL cardiovascular outcomes trial timeline update, positive CVOT readout, and 2027 launch "could represent major near-term inflections."
